Gender differences in liver disease and the drug-dose gender gap

Pharmacol Res. 2017 Jun:120:97-108. doi: 10.1016/j.phrs.2017.03.014. Epub 2017 Mar 20.

Abstract

Although gender-based medicine is a relatively recent concept, it is now emerging as an important field of research, supported by the finding that many diseases manifest differently in men and women and therefore, might require a different treatment. Sex-related differences regarding the epidemiology, progression and treatment strategies of certain liver diseases have long been known, but most of the epidemiological and clinical trials still report results only about one sex, with consequent different rate of response and adverse reactions to treatment between men and women in clinical practice. This review reports the data found in the literature concerning the gender-related differences for the most representative hepatic diseases.

Keywords: Gender; Liver disease; Liver toxicity; Systematic review.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Budd-Chiari Syndrome / drug therapy
  • Budd-Chiari Syndrome / epidemiology
  • Budd-Chiari Syndrome / pathology
  • Chemical and Drug Induced Liver Injury / drug therapy
  • Chemical and Drug Induced Liver Injury / epidemiology
  • Chemical and Drug Induced Liver Injury / pathology
  • Dose-Response Relationship, Drug
  • Female
  • Hemochromatosis / drug therapy
  • Hemochromatosis / epidemiology
  • Hemochromatosis / pathology
  • Hepatitis / drug therapy
  • Hepatitis / epidemiology
  • Hepatitis / pathology
  • Humans
  • Liver / drug effects*
  • Liver / pathology*
  • Liver Diseases / drug therapy*
  • Liver Diseases / epidemiology*
  • Liver Diseases / pathology
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / epidemiology
  • Liver Neoplasms / pathology
  • Male
  • Non-alcoholic Fatty Liver Disease / drug therapy
  • Non-alcoholic Fatty Liver Disease / epidemiology
  • Non-alcoholic Fatty Liver Disease / pathology
  • Sex Factors